Hypoglycemic therapy in patients with type 2 diabetes and chronic heart failure

Cover Page

Cite item

Full Text

Abstract

The article presents a literature review of prevalence, prognosis and treatment of overt tactics of chronic heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM). Application of modern pharmacological preparations and instrumental treatment of cardiovascular disease (CVD) increases life expectancy and improves the quality of life of patients with CHF as with normal carbohydrate metabolism (UO), and with type 2 diabetes. However, the risk of cardiovascular mortality (CAS) in patients with type 2 diabetes, compared to having a normal carbohydrate metabolism remains unchanged.Insulin resistance (IR) and compensatory hyperinsulinemia (GI) play a key role in the pathogenesis of type 2 diabetes. Ongoing research in the twentieth century of coronary heart disease (CHD) and heart failure in patients with type 2 diabetes revealed adverse effects of sulfonylurea medications on the metabolic processes in the myocardium and increased risk of death in patients with severe coronary artery disease. In comparison with sulfonylurea drugs, metformin and insulin not only reduces the risk of cardiovascular disease, but also can prevent or delay the development of type 2 diabetes in individuals with impaired glucose tolerance (IGT) and impaired fasting glucose. Metformin acts on the key link of pathogenesis - insulin resistance, affecting the lower incidence of cardiovascular diseases, the development of chronic disease and mortality compared with insulin and sulfonylurea drugs. However, in patients with chronic heart failure is contraindicated the use of thiazolidinediones and metformin is limited tothe severity of CHF I-II FC NYNA. With effective treatment of chronic heart failure by cardiologists in patients with type 2 diabetes, affecting therapy with insulin resistance should be mandatory.

About the authors

S. V Kakorin

MoscowCity Clinical Hospital №4

Email: kakorin-s@yandex.ru
канд. мед. наук, зав. отд-нием неотложной кардиологии

I. A Averkova

Evdokimov Moscow State University of Medicine and Dentistry

ассистент каф. эндокринологии и диабетологии

A. M Mkrtumyan

Evdokimov Moscow State University of Medicine and Dentistry

д-р мед. наук, проф., зав. каф. эндокринологии и диабетологии

References

  1. Викулова О.К., Шестакова М.В. Терапия глибенкламидом: за или против? Сахарный диабет. 2011; 3: 92-5.
  2. Standi E. Aetiology and consenquences of the metabolic syndrome. Eur Heart J 2005; 7: 10-3.
  3. Midaoui A, Champlain J. Effects of glucose and insulin on the development of oxidative stress and hypertension in animal models of type 1 and type 2 diabetes. Hypertension 2005; 23 (3): 581-8.
  4. Демидова Т.Ю. Этиопатогенетическая роль инсулинорезистентности в развитии метаболических и сосудистых нарушений при сахарном диабете 2 типа. Фарматека. 2010; 16:18-24.
  5. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54 (5): 422-8.
  6. Chris P.H, Lexis, Braim M Rahel, Joan G Meeder et al. Cardiovascular Diabetology 2009; 8: 41; doi: 10.1186/1475-2840-8-41
  7. Аметов А.С. Инсулиносекреция и инсулинорезистентность: две стороны одной медали. Проблемы эндокринологии. 2002; 48 (3): 31-6.
  8. Ingelsson E, Sundstrom J, Arnlov J et al. Insulin resistance and risk of congestive heart failure JAMA 2005; 294: 334-40.
  9. Prior J, Quinones M, Hernandez-Pampaloni M et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005; 111: 2291-8.
  10. Global Guideline for Type 2 Diabetes. International Diabetes Federation 2005; р. 35-6.
  11. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Изд. 6-е. Под ред. И.И.Дедова, М.В.Шестаковой. М., 2013; с. 60.
  12. Kirpichnikov D, Mc Farlane S, Sowers J. Metformin: An Update. Ann Intern Med 2002; 137: 25-33.
  13. Mc Donald A, Eurich D.T, Mayumidar S.R. Treatment of type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case - Control Study From UK General Practice Research Datebase. Diabetes Care 2010; 33: 1210-9.
  14. Johnson J, Simpson S, Toth E, Majumdar S. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 2005; 22: 497-502.
  15. Eurich D, Majumdar S, Mc Alister F et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-51.
  16. Curtis J, Wilson C. Preventing type 2 diabetes mellitus. J Am Board Fam Pract 2005; 18 (1): 37-43.
  17. Смирнова О.М., Кононенкова И.М. Гипогликемизирующая терапия больных сахарным диабетом 2 типа и ишемической болезнью сердца, в том числе с инфарктом миокарда и после интервенционных вмешательств. Сахарный диабет. 2012; (3): 27-38.
  18. Monami M, Luzzi C, Chiasserini V et al. Three - year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 2006; 22: 477-82.
  19. Трунина Е.Н., Петунина Н.А., Чорбинская С.А. Ингибиторы дипептидилпептидазы-4 в лечении сахарного диабета 2 типа. Возможности кардиопротекции. Сахарный диабет. 2011; 2: 59-64.
  20. Cabou C, Campistron G, Marsollier N et al. Brain glucagon - like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008; 57 (10): 2577-87.
  21. Bullock B.P, Heller R.S, Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon - like peptide-1 receptor. Endocrinology 1996; 137: 2968-78.
  22. Campos R.V, Lee Y.C, Drucker D.J. Divergent tissue - specific and developmental expression of receptors for glucagon and glucagonlike peptide-1 in the mouse. Endocrinology 1994; 134: 2156-64.
  23. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco - incretin hormone glucagon - like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-5.
  24. Bose A.K, Mocanu M.M, Carr R.D et al. Glucagonlike peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005; 54: 146-51.
  25. Zhao T, Parikh P, Bhashyam S et al. Direct effects of glucagon - like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 1106-13.
  26. Александров А.А. Сахарный диабет и гормональная энтерология: путь в прекрасное далеко. Сахарный диабет. 2001; 2: 41-8.
  27. Sokos G.G et al. Glucagon - like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-9.
  28. Nikolaidis L.A et al. Effects of glucagon - like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-5.
  29. Pi-Sunyer F.X, Aronne L.J, Heshmati H.M et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: Rio-North America: A randomized controlled trial. JAMA 2006; 295: 761.
  30. Шестакова М.В. Лираглутид - возможности комплексного терапевтического подхода в терапии СД 2 типа. Сахарный диабет. 2009; 5: 3-6.
  31. Sakharova O.V, Inzucchi S.E. Treatment of diabetes in the elderly. Addressing its complexities in this high - risk group. Postgrad Med 2005; 118 (5): 19-26.
  32. Blonde L et al. Gastrointestinal tolerability of extended - release metformin tablets compared to immediate - release metformin tablets: results of a retrospective cohort study. Curr Med Res Opinm 2004; 20 (4): 565-72.
  33. Мкртумян А.М. Оптимизация лечения сахарного диабета 2 типа: комбинированная терапия фиксированной дозой Амарила и метформина (Амарил М). Эффективная фармакотерапия. 2011; 2: 3-10.
  34. Александров А.А. Кардиальные свойства сахароснижающих препаратов. Сульфаниламиды и сердце. Сердце. 2004; 3 (1):34-5.
  35. Inzucchi S.E, Bergenstal R.M, Buse J.B et al. Management of hyperglycaemia in type2 diabetes: a patient - centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55 (6): 1577-96. Doi: http://dx.doi.org/10.1007/s00125-012-2534-0
  36. International Diabetes Federation treatment algorithm for people with type 2 diabetes. 2012. Available from: http://www.idf.org/Global_guideline
  37. Gangji A.S, Cukierman T, Gerstein H.C et al. A systematic review and meta - analysis f hypoglycemia and cardiovascular events. A comparison of glyburide with other secretagogues and insulin. Diabetes care 2007; 30 (2): 389-94.
  38. Turner R.C et al. JAMA 1999; 281: 2005-12.
  39. Garber A, Donovan D, Bruce S, Park J-S. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrin Metab 2003; 88 (8): 3598-604.
  40. Fisman E.Z, Tenenbaum A, Boyko V et al. Oral antidiabetic trea tment in patients with coronary disease: time - related increased mortality on combined gliburid/metformin therapy over a 7,7-year follow - up. Clin Cardiol 2001; 24 (2): 151-8.
  41. Смирнова О.М. Нужен ли контроль гликемии при сахарном диабете: за и против. Эффективная фармакотерапия. 2011; с. 16-21.
  42. Schramm T.K, Gislason G.H, Vaag A et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; doi: 10.1093/eurheartj/ehr077
  43. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide - related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009; 86: 247-53.
  44. Zeller M, Danchin N, Simon D et al. Impact f type preadmission sulphonylureas on mortality and cardiovascular outcmes in diabetic patients with acute myocardial infarction. J Clin Endocrin Metab 2010; doi: 10.1210/jc.2010-0449
  45. Salas M, Caro J.J. Are hypoglycemia and other adverse effects similar among sulphonylureas. Advers Drug react Toxicol Rev 2002; 21: 205-17.
  46. Wei M, Gibbons L.W, Mitchell T.L et al. Low fasting plasma glucose level as a predictor of cardiovascular disease and all - cause mortality. Circulation 2000; 101 (17): 2047-52.
  47. Kitsios K, Tsapas A, Karagianni P. Glycemia and cardiovascular risk: challenging evidence based medicine Hippokratia 2011; 15 (3):199-204.
  48. Mannucci E, Monami M, Masotti G, Marchionni N. All - cause mortality in diabetic patients treated with combination of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004; 20 (1): 44-7.
  49. UK Prospective Diabetes Study Group. Intensive blood - glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33. Lancet 1998; 352 (12): 837-53.
  50. Лапина Ю.В. Оценка взаимного влияния хронической сердечной недостаточности и сахарного диабета 2 типа на клиническое состояние больных в процессе длительной комплексной терапии. Дис. ... канд. мед. наук. М., 2008.
  51. Недосугова Л.В. Роль препаратов сульфонилмочевины в развитии сердечно - сосудистых осложнений при сахарном диабете 2 типа. Сахарный диабет. 2013; (2): 26-35.
  52. Temelkova-Kurktschiev T, Henkel E, Koehler C et al. Subclinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002; 45: 151-6.
  53. Ceriello A, Esposito K, Piconi L et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57: 1349-54.
  54. Van Melle J.P, Bot M, de Jonge P et al. Diabetes, Glycemic Control, and New-Onset Heart Failure in Patients With Stable Coronary Artery Disease. Diabetes Care 2010; 33 (9): 2084-9.
  55. Knatterad G.L, Klimt C.R, Levin M.E et al. Effects of hypoglycemic agents on vascular complications in patients with adult - onset diabetes. JAMA 1978; 240: 37-42.
  56. Saito I, Folsom A.R, Brancati F.L et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133: 81-91.
  57. Abraira С, Colwell J.A, Nuttall F.Q et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Int Med 1997; 157: 181-8.
  58. Pitale S.U, Abraira C, Emanuele N.V et al. Two years of intensive glycemic control and left ventricular function in the Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus (VA CSDM). Diabetes Care 2000; 23: 1316-20.
  59. Eurich D.T, Mc Alister F.A, Blackburn D.F, Majumdar S.R. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497.
  60. Майоров А.Ю., Науменкова И.В. Современные сахароснижающие средства в лечении сахарного диабета 2 типа. Рус. мед. журн. 2001; 24 (9): 1105-12.
  61. Nathan D.M, Buse J.B, Davidson M.B et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29 (8): 1963-72.
  62. Hemmingsen B, Christensen L.L, Wetterslev J et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta - analyses and trial sequential analyses. BMJ 2012; 344: e1771.
  63. Nathan D.M, Buse J.B, Davidson M.B et al. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (ADA-EASD). Diabetologia 2008; 51: 8-11.
  64. Ryden L, Standi E, Bartnik M et al. Guidelines on diabetes, pre - diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
  65. Бирюкова Е.В. Эффективный и безопасный контроль гликемии с помощью препарата Глюкофаж Лонг - залог успешной профилактики сосудистых осложнений. Рос. мед. журн. 2013; 4: 194-8.
  66. Викулова О.К. Выбор тактики лечения у пациентов с неудовлетворительной компенсацией сахарного диабета 2 типа: возможности назначения миметика инкретинов эксенатида (на примере клинического случая). Сахарный диабет. 2008; 4: 84-8.
  67. Майоров А.Ю., Шамхалова М.Ш. 72-й Ежегодный конгресс Американской диабетической ассоциации (ADA), 8-12 июня 2012 г. Филадельфия. Сахарный диабет. 2012; (2): 109-10.
  68. Дедов И.И., Шестакова М.В., Аметов А.С. и др. Проект «Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии сахарного диабета 2 типа». Сахарный диабет. 2011; 1: 98-108.
  69. Executive Summary: Standards of Medical Care in Diabetes Diabetes Care 2013; 36 (Suppl. 1): S4-S10.
  70. Аметов А.С., Карпова Е.В. Эффективность терапии ингибиторами ДПП-4 в комбинации с базальным инсулином у больных сахарным диабетом 2 типа. Сахарный диабет. 2011; 4:55-9.

Copyright (c) 2014 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies